## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Vinva Investment Management Ltd Increases Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251129T115251 | Somewhat-Bullish | Relevance: 99%
- Vinva Investment Management Ltd increased its stake in Danaher Corporation ($DHR) by 31.7% in Q2, acquiring an additional 10,635 shares to hold a total of 44,202 shares valued at approximately $8.79 million. Wall Street analysts maintain a "Moderate Buy" consensus rating for DHR with an average target price of $243.39, despite recent insider selling totaling about $6.61 million. The article also details other institutional investor activities, analyst ratings, and the company's financial performance.

**2. Danaher Corporation $DHR Shares Purchased by Scotia Capital Inc.**
- Source: MarketBeat | 20251129T130558 | Somewhat-Bullish | Relevance: 99%
- Scotia Capital Inc. significantly increased its stake in Danaher Corporation by 6.0% in Q2, acquiring an additional 25,169 shares. This purchase brings their total ownership to 445,480 shares, valued at approximately $87,999,000. Meanwhile, company insiders have been net sellers, disposing of over 30,000 shares worth $6.61 million in the last 90 days.

**3. Danaher Corporation (DHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: ABC4 Utah | 20251130T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Danaher Corporation (NYSE: DHR) on behalf of investors who purchased securities before April 21, 2022, and still hold them. The investigation aims to determine if Danaher and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information and to assist with the investigation, emphasizing that there is no cost to the investors.

**4. Danaher Corporation (DHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: CW39 Houston | 20251130T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (NYSE:DHR) securities. The investigation focuses on whether Danaher and its officers engaged in corporate wrongdoing. Stockholders who purchased shares prior to April 21, 2022, are encouraged to contact the firm for more information.

**5. Choreo LLC Has $3.69 Million Stock Position in Danaher Corporation $DHR**
- Source: MarketBeat | 20251129T085049 | Bullish | Relevance: 99%
- Choreo LLC substantially increased its stake in Danaher Corporation by 23.1%, now holding 18,636 shares worth approximately $3.69 million. Analysts maintain a "Moderate Buy" consensus for Danaher with an average target price of $243.39, despite recent insider stock sales totaling $6.61 million. The company recently reported strong quarterly earnings, beating analyst expectations for both EPS and revenue.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.6x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $165.0B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.6 |
| Current P/E | 29.1 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.6% to -2.7% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.74% (CS: 17) | Weak |
| RSI_14 | 57.0 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.14
- **Stop Loss:** $213.86 (4.6% risk)
- **Target:** $234.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $16,138.08
- **Portfolio %:** 16.14%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*